CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19 (CRISIS2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04575038|
Recruitment Status : Completed
First Posted : October 5, 2020
Results First Posted : April 19, 2022
Last Update Posted : April 19, 2022
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|COVID-19 Infection||Drug: Brequinar Drug: Placebo||Phase 2|
Brequinar is a potent DHODH inhibitor that has been previously studied in more than 1,000 cancer, psoriasis, and organ transplant patients. Brequinar has been found to have potent in vitro antiviral activity against many RNA viruses including SARS-CoV-2. The antiviral activity of brequinar against SARS-CoV-2 is likely due to DHODH inhibition and shows nanomolar potency and a high selectivity index in inhibiting viral replication in in vitro studies.
The CRISIS2 trial will study out-patients (non-hospitalized patients) who have a positive SARS-CoV-2 test and are symptomatic. Subjects will be randomized to receive standard of care (SOC) + 5 days of brequinar or SOC + 5 days of placebo. The purpose of this study is to determine if the in vitro antiviral activity of brequinar can be duplicated in patients infected with SARS-CoV-2 by measuring the effect of brequinar on viral shedding. Importantly, the safety and tolerability of brequinar will also be determined in these patients. The results of this proof-of-concept study will inform future studies that will help determine if brequinar is a safe and effective drug for the treatment of SARS-CoV-2 infection.
This will be a phase II randomized, placebo-controlled, double blind, multi-center study with approximately 100 subjects. All subjects will receive standard of care (SOC) per institutional guidelines for treatment of patients with COVID-19 infection. In addition to SOC, the subjects will self-administer one capsule once daily for 5 days.
Subjects will have a Screening Visit followed as soon as possible with Study Day 1. Study visits (virtual or in person) will take place at Screening and on specified days. The visits that include bloodwork must be conducted at the study site or arrangements made for sample collection at the subject's home or other appropriate location. Other visits/visit activities for that visit may be conducted remotely using telemedicine or other remote technique. Subjects are to self-collect a viral load sample, obtain their respiratory rate, heart rate, body temperature and SpO2, and complete a symptom assessment checklist on specified days.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||115 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Randomized 1:1 brequinar 100 mg or placebo|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Masking Description:||Double blind|
|Official Title:||The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2|
|Actual Study Start Date :||November 19, 2020|
|Actual Primary Completion Date :||April 28, 2021|
|Actual Study Completion Date :||April 28, 2021|
Experimental: Brequinar 100 mg
Brequinar oral capsules 100 mg x 5 days
Dihydroorotate dehydrogenase inhibitor (DHODHi)
Placebo Comparator: Placebo
Placebo for Brequinar capsules x 5 days
- Log10 SARS-CoV-2 Viral Load [ Time Frame: Days 4, 8, 12, 15, 22, and 29 ]Median Change from Baseline in Quantitative Log10 SARS-CoV-2 viral load at Days 4, 8, 12, 15, 22, and 29.
- Rates of AEs and SAEs Including Laboratory Assessments [ Time Frame: Through Day 29 ]Safety measured by number of participants with AEs and SAEs including laboratory assessments.
- Viral Shedding Duration [ Time Frame: Through Day 36 ]Duration of viral shedding was defined as the time to viral clearance (two consecutive negative test results) for the Microbiology Evaluable Set population.
- Hospital Admission [ Time Frame: Day 29 ]Percentage of subjects requiring admission as an inpatient for >24 hours
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Willing and able to provide informed consent for the trial, written, electronic, verbal or other method deemed acceptable by the institution and IRB.
- 18 years of age or older.
- Laboratory-confirmed SARS-CoV-2 infection as determined by real time polymerase chain reaction (RT-PCR) or other FDA-approved commercial or public health assay.
- Out-patient (never hospitalized as an in-patient for COVID-19 or was evaluated/treated for COVID-19 only in the Emergency Room with a stay of < 24 hours)
- The effects of brequinar on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men and women treated or enrolled on this protocol must also agree to use adequate contraception for the duration of study participation, and for 90 days after completion of brequinar administration.
- Male subjects must agree to refrain from sperm donation and female subjects must agree to refrain from ovum donation from initial study drug administration until 90 days after the last dose of brequinar.
- Must have at least one COVID-19 symptom including but not limited to fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, shortness of breath, dyspnea, anosmia, dysgeusia, or other symptom commonly associated with COVID-19 in the opinion of the investigator. Symptom onset must be ≤7 days prior to first dose. Subject must have one or more symptoms at first dose.
- Able to swallow capsules.
- Any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient
- Nursing women or women of childbearing potential (WOCBP) with a positive pregnancy test
- Treatment with another DHODH inhibitor (e.g., leflunomide, teriflunomide) or other agents known to cause bone marrow suppression leading to thrombocytopenia
- Platelets ≤150,000 cell/mm3
- Hemoglobin < 10 gm/dL
- Absolute neutrophil count < 1500 cells/mm3
- Renal dysfunction, i.e., creatinine clearance < 30 mL/min
- AST or ALT > 2 x ULN, or total bilirubin > ULN. Gilbert's Syndrome is allowed.
- Bleeding disorders or blood loss requiring transfusion in the six weeks preceding enrollment
- Ongoing gastrointestinal ulcer, or gastrointestinal bleeding within 6 weeks of randomization.
- Chronic hepatitis B infection, active hepatitis C infection, active liver disease and/or cirrhosis per subject report.
- Heart failure, current uncontrolled cardiovascular disease, including unstable angina, uncontrolled arrhythmias, major adverse cardiac event within 6 months (e.g. stroke, myocardial infarction, hospitalization due to heart failure, or revascularization procedure).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04575038
|United States, Alabama|
|Central Alabama Research|
|Homewood, Alabama, United States, 35209|
|United States, California|
|Ark Clinical Research|
|Long Beach, California, United States, 90806|
|United States, Florida|
|Doral Medical Research|
|Doral, Florida, United States, 33166|
|United States, New Jersey|
|South Jersey Infectious Disease|
|Somers Point, New Jersey, United States, 08244|
|United States, North Carolina|
|Monroe Biomedical Research|
|Monroe, North Carolina, United States, 28112|
|Wilmington, North Carolina, United States, 28401|
|United States, Ohio|
|Columbus, Ohio, United States, 43215|
|Toledo Institute of Clinical Research|
|Toledo, Ohio, United States, 43617|
|United States, South Carolina|
|VitaLink - Gaffney|
|Gaffney, South Carolina, United States, 29615|
|Self Regional Healthcare Research Center - Self Medical Group|
|Greenwood, South Carolina, United States, 29646|
|Spartanburg, South Carolina, United States, 29303|
|United States, Tennessee|
|Clinical Trials Center of Middle Tennessee|
|Franklin, Tennessee, United States, 37067|
|United States, Texas|
|Centex Studies, Inc. - McAllen|
|McAllen, Texas, United States, 78504|
|United States, Utah|
|Synexus Clinical Research US, Inc. - Olympus Family Medicine|
|Salt Lake City, Utah, United States, 84117|
Documents provided by Clear Creek Bio, Inc.:
|Responsible Party:||Clear Creek Bio, Inc.|
|Other Study ID Numbers:||
|First Posted:||October 5, 2020 Key Record Dates|
|Results First Posted:||April 19, 2022|
|Last Update Posted:||April 19, 2022|
|Last Verified:||April 2022|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Respiratory Tract Infections
RNA Virus Infections
Respiratory Tract Diseases
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs